The Role of MAPK's Signaling in Mediating ApoE4-Driven Pathology In Vivo
Authors:
- 24 April 2019
- journal article
- research article
- Published by Bentham Science Publishers Ltd. in Current Alzheimer Research
- Vol. 16 (4) , 281-292
Abstract
Background: Alzheimer's Disease (AD) is associated with impairments in key brain Mitogen- Activated Protein Kinase (MAPK) signaling cascades including the p38, c-Jun N-terminal kinase (JNK), ERK and Akt pathways. Apolipoprotein E4 (ApoE4) is the most prevalent genetic risk factor of AD. Objectives: To investigate the extent to which the MAPK signaling pathway plays a role in mediating the pathological effects of apoE4 and can be reversed by experimental manipulations. Methods: Measurements of total level and activation of MAPK signaling pathway factors, obtained utilizing immunoblot assay of hippocampal tissues from naïve and viral-treated apoE3 and apoE4 targeted replacement mice. Methods: Measurements of total level and activation of MAPK signaling pathway factors, obtained utilizing immunoblot assay of hippocampal tissues from naïve and viral-treated apoE3 and apoE4 targeted replacement mice. Results: ApoE4 mice showed robust activation of the stress related p38 and JNK pathways and a corresponding decrease in Akt activity, which is coupled to activation of GSK3β and tau hyperphosphorylation. There was no effect on the ERK pathway. We have previously shown that the apoE4- related pathology, namely; accumulation of Aβ, hyper-phosphorylated tau, synaptic impairments and decreased VEGF levels can be reversed by up-regulation of VEGF level utilizing a VEGF-expressing adeno-associated virus. Utilizing this approach, we assessed the extent to which the AD-hallmark and synaptic pathologies of apoE4 are related to the corresponding MAPK signaling effects. This revealed that the reversal of the apoE4-driven pathology via VEGF treatment was associated with a reversal of the p38 and Akt related effects. Conclusion: Taken together, these results suggest that the p38 and Akt pathways play a role in mediating the AD-related pathological effects of apoE4 in the hippocampus.Keywords
Funding Information
- Israel Science Foundation (794/17)
This publication has 53 references indexed in Scilit:
- ApoE4 induces Aβ42, tau, and neuronal pathology in the hippocampus of young targeted replacement apoE4 miceMolecular Neurodegeneration, 2013
- Apolipoprotein E4 Impairs Macrophage Efferocytosis and Potentiates Apoptosis by Accelerating Endoplasmic Reticulum StressJournal of Biological Chemistry, 2012
- Microarray analysis of the astrocyte transcriptome in the aging brain: relationship to Alzheimer’s pathology and APOE genotypeNeurobiology of Aging, 2011
- ApoE4 reduces glutamate receptor function and synaptic plasticity by selectively impairing ApoE receptor recyclingProceedings of the National Academy of Sciences, 2010
- Targeting p38 MAPK pathway for the treatment of Alzheimer's diseaseNeuropharmacology, 2010
- The Role of Apolipoprotein E in Alzheimer's DiseaseNeuron, 2009
- The GSK3 hypothesis of Alzheimer’s diseaseJournal of Neurochemistry, 2007
- APOE4 -VLDL Inhibits the HDL-Activated Phosphatidylinositol 3-Kinase/Akt Pathway via the Phosphoinositol Phosphatase SHIP2Circulation Research, 2006
- Multiple pathways of apolipoprotein E signaling in primary neuronsJournal of Neurochemistry, 2005
- The Role of Mitogen-Activated Protein Kinase Pathways in Alzheimer’s DiseaseNeurosignals, 2002